Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review

Kenneth H Mayer, Allison Agwu, David Malebranche, Kenneth H Mayer, Allison Agwu, David Malebranche

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first approved by the US Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest where PrEP has been deployed, the uptake of PrEP is lagging, particularly among populations with disproportionate HIV burden. This narrative review seeks to identify individual and systemic barriers to PrEP usage in the USA. A comprehensive search of recent literature uncovered a complex array of structural, social, clinical, and behavioral barriers, including knowledge/awareness of PrEP, perception of HIV risk, stigma from healthcare providers or family/partners/friends, distrust of healthcare providers/systems, access to PrEP, costs of PrEP, and concerns around PrEP side effects/medication interactions. Importantly, these barriers may have different effects on specific populations at risk. The full potential of PrEP for HIV prevention will not be realized until these issues are addressed. Strategies to achieve this goal should include educational interventions, innovative approaches to delivery of HIV care, financial support, and destigmatization of PrEP and PrEP users. Until then, PrEP uptake will continue to be suboptimal, particularly among those who need it most.

Keywords: Access; Barriers; Distrust; Emtricitabine; Implementation; Pre-exposure prophylaxis; Prevention; Stigma; Tenofovir alafenamide; Tenofovir disoproxil fumarate.

References

    1. Centers for Disease Control and Prevention. Application number: 021752Orig1s030 summary review; 2012. . Accessed 1 July 2019.
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
    1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
    1. Sullivan PS, Smith DK, Mera-Giler R, et al. The impact of pre-exposure prophylaxis with TDF/FTC on HIV diagnoses, 2012–2016, United States. 22nd International AIDs conference 2018, Amsterdam.
    1. Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. Ann Epidemiol. 2018;28:833–840.
    1. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28:850–857.
    1. Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67:1147–1150.
    1. Centers for Disease Control and Prevention. HIV surveillance report; 2017. . Accessed 1 July 2019.
    1. Edelman EJ, Moore BA, Calabrese SK, et al. Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2017;21:1025–1033.
    1. Marks SJ, Merchant RC, Clark MA, et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDS. 2017;31:470–478.
    1. Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841–849.
    1. Centers for Disease Control and Prevention. HIV in the United States by region; 2018. . Accessed 1 July 2019.
    1. McMahan VM, Martin A, Garske L, et al. Development of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA) Sex Health. 2019;16:139–147.
    1. Louisiana HealthHub. What is the TelePrEP program? . Accessed 15 Aug 2019.
    1. Harawa NT, Bempong GA, Fields S, et al. Engaging black men who have sex with men (BMSM) in Los Angeles in HIV pre-exposure prophylaxis (PrEP). California HIV/AIDS Policy Centers; 2016.
    1. Kwa S, Ma Y. Increase in willingness to take pre-exposure prophylaxis among men who have sex with men in Los Angeles, 2011 to 2014. Los Angeles County Department of Public Health Conference; 2015.
    1. Galang RR, Mendoza MCB, Smith DK. HIV preexposure prophylaxis among U.S. adults: awareness of and willingness to recommend or take—HealthStyles Surveys, 2009–2014. J Prev Treat HIV/AIDS. 2017;2.
    1. Storrow L, Montenegro J. Advancing HIV prevention through public opinion polling: lessons from the southern United States. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Shende T, Fisher J, Perez-Velez C, et al. PrEP knowledge and attitudes among adults attending public health clinics in Southern Arizona. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Gomar Ramirez C. Identifying and addressing barriers to pre-exposure prophylaxis initiation via telecommunication intervention in urban NYC. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Farthing H, Rodriguez A, Armstrong M, et al. Discomfort discussing HIV/AIDS and lack of awareness are barriers to partner-to-partner pre-exposure prophylaxis education. Int J STD AIDS. 2019;30:147–153.
    1. Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19:802–810.
    1. Zhang HL, Rhea SK, Hurt CB, et al. HIV preexposure prophylaxis implementation at local health departments: a statewide assessment of activities and barriers. J Acquir Immune Defic Syndr. 2018;77:72–77.
    1. Bagchi AD, Holzemer W. Support for PrEP among New Jersey health care workers. J Assoc Nurses AIDS Care. 2018;29:849–857.
    1. Ellis M, Scroggins S, Shacham E, Moore K. Training, communication, and prescribing patterns of pre-exposure prophylaxis (PrEP) among a sample of nurse practitioners in the United States: important gaps and opportunities. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Gunn LH, Janson B, Lorjuste I, Summers L, Burns P, Bryant T., 3rd Healthcare providers’ knowledge, readiness, prescribing behaviors, and perceived barriers regarding routine HIV testing and pre-exposure prophylaxis in DeLand, Florida. SAGE Open Med. 2019;7:2050312119836030.
    1. Wood BR, McMahan VM, Naismith K, Stockton JB, Delaney LA, Stekler JD. Knowledge, practices, and barriers to HIV preexposure prophylaxis prescribing among Washington State medical providers. Sex Transm Dis. 2018;45:452–458.
    1. Ojile N, Sweet D, Kallail KJ. A preliminary study of the attitudes and barriers of family physicians to prescribing HIV preexposure prophylaxis. Kans J Med. 2017;10:40–42.
    1. Hoffman S, Guidry JA, Collier KL, et al. A clinical home for preexposure prophylaxis: diverse health care providers’ perspectives on the “purview paradox”. J Int Assoc Provid AIDS Care. 2016;15:59–65.
    1. Mayer KH, Allan-Blitz LT. PrEP 1.0 and beyond: optimizing a biobehavioral intervention. J Acquir Immune Defic Syndr. 2019;82(Suppl 2):S113–S117.
    1. Mullins TLK, Idoine CR, Zimet GD, Kahn JA. Primary care physician attitudes and intentions toward the use of HIV pre-exposure prophylaxis in adolescents in one metropolitan region. J Adolesc Health. 2019;64:581–588.
    1. Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre-exposure prophylaxis. Drugs. 2019;79:609–619.
    1. Centers for Disease Control and Prevention, US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. . Published March 2018; 2017.
    1. Kwakwa HA, Bessias S, Sturgis D, et al. Attitudes toward HIV pre-exposure prophylaxis in a United States urban clinic population. AIDS Behav. 2016;20:1443–1450.
    1. Braksmajer A, Leblanc NM, El-Bassel N, Urban MA, McMahon JM. Feasibility and acceptability of pre-exposure prophylaxis use among women in violent relationships. AIDS Care. 2019;31:475–480.
    1. Wendlandt R, Salazar LF, Mijares A, Pitts N. Gender-based violence and HIV risk among African American women: a qualitative study. J HIV AIDS Soc Serv. 2016;15:83–98.
    1. Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care. 2018;30:1282–1289.
    1. Fisher CB, Fried AL, Desmond M, Macapagal K, Mustanski B. Facilitators and barriers to participation in PrEP HIV prevention trials involving transgender male and female adolescents and emerging adults. AIDS Educ Prev. 2017;29:205–217.
    1. Kahle EM, Sharma A, Sullivan SP, Stephenson R. HIV prioritization and risk perception among an online sample of men who have sex with men in the United States. Am J Mens Health. 2018;12:676–687.
    1. Oldenburg CE, Mitty JA, Biello KB, et al. Differences in attitudes about HIV pre-exposure prophylaxis use among stimulant versus alcohol using men who have sex with men. AIDS Behav. 2016;20:1451–1460.
    1. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33:1411–1420.
    1. Blank MB, Himelhoch SS, Balaji AB, et al. A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health. 2014;104:2377–2384.
    1. Himelhoch S, Goldberg R, Calmes C, et al. Screening for and prevalence of HIV and hepatitis C among an outpatient urban sample of people with serious mental illness and co-occurring substance abuse. J Community Psychol. 2011;39:231–239.
    1. Cornelius T, Jones M, Merly C, Welles B, Kalichman MO, Kalichman SC. Impact of food, housing, and transportation insecurity on ART adherence: a hierarchical resources approach. AIDS Care. 2017;29:449–457.
    1. Flash CA, Dale SK, Krakower DS. Pre-exposure prophylaxis for HIV prevention in women: current perspectives. Int J Womens Health. 2017;9:391–401.
    1. Brinkley-Rubinstein L, Peterson M, Arnold T, et al. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. PLoS One. 2018;13:e0205593.
    1. Gelberg L, Gallagher TC, Andersen RM, Koegel P. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. Am J Public Health. 1997;87:217–220.
    1. Carter GA, Jayawardene W, Agley J, et al. Development of a 10-item tool to identify advanced practice nurse readiness to prescribe pre-exposure prophylaxis. J Assoc Nurses AIDS Care. 2019;30:312–320.
    1. Calabrese SK, Earnshaw VA, Underhill K, et al. Prevention paradox: medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. J Int AIDS Soc. 2018;21:e25147.
    1. Rael CT, Martinez M, Giguere R, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22:3627–3636.
    1. Dubov A, Galbo P, Jr, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Mens Health. 2018;12:1843–1854.
    1. Duran D. Truvada whores? 2012. . Accessed 2 Sep 2019.
    1. Blackstock OJ, Moore BA, Berkenblit GV, et al. A cross-sectional online survey of HIV pre-exposure prophylaxis adoption among primary care physicians. J Gen Intern Med. 2017;32:62–70.
    1. Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15:190–197.
    1. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58:704–712.
    1. Marcus JL, Katz KA, Krakower DS, Calabrese SK. Risk compensation and clinical decision making—the case of HIV preexposure prophylaxis. N Engl J Med. 2019;380:510–512.
    1. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18:226–240.
    1. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health. 2015;105:e60–e76.
    1. Maina IW, Belton TD, Ginzberg S, Singh A, Johnson TJ. A decade of studying implicit racial/ethnic bias in healthcare providers using the implicit association test. Soc Sci Med. 2018;199:219–229.
    1. Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M. Injustice at every turn: a report of the national transgender discrimination survey; 2011. . Accessed 11 Nov 2018.
    1. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366:447–453.
    1. Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29:102–110.
    1. Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21:879–897.
    1. Kemet S. Insight medicine lacks—the continuing relevance of Henrietta Lacks. N Engl J Med. 2019;381:800–801.
    1. Spector-Bagdady K, Lombardo PAUS. Public Health Service STD experiments in Guatemala (1946–1948) and their aftermath. Ethics Hum Res. 2019;41:29–34.
    1. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr. 2005;38:213–218.
    1. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr. 2010;53:648–655.
    1. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. 2017;21:1236–1246.
    1. Brooks RA, Allen VC, Jr, Regan R, Mutchler MG, Cervantes-Tadeo R, Lee SJ. HIV/AIDS conspiracy beliefs and intention to adopt preexposure prophylaxis among black men who have sex with men in Los Angeles. Int J STD AIDS. 2018;29:375–381.
    1. Olansky E, Mansergh G, Pitts N, et al. PrEP awareness in the context of HIV/AIDS conspiracy beliefs among black/African American and Hispanic/Latino MSM in three urban US cities. J Homosex. 2019 doi: 10.1080/00918369.2018.1557953.
    1. US Food and Drug Administration. Final report on the dialogues on diversifying clinical trials conference. . Accessed 9 Oct 2019.
    1. Andrasik MP, Chandler C, Powell B, et al. Bridging the divide: HIV prevention research and Black men who have sex with men. Am J Public Health. 2014;104:708–714.
    1. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19:21105.
    1. Greene GJ, Nery-Hurwit M, Matson M, Macapagal K. Perceived barriers to emerging PrEP modalities in the US: social determinants of health and modality-specific attributes may inhibit PrEP uptake among sexual and gender minority adolescents. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Felsher M, Szep Z, Krakower D, Martinez-Donate A, Tran N, Roth AM. “I don’t need PrEP right now”: a qualitative exploration of the barriers to PrEP care engagement through the application of the health belief model. AIDS Educ Prev. 2018;30:369–381.
    1. Rice WS, Stringer KL, Sohail M, et al. Accessing pre-exposure prophylaxis (PrEP): perceptions of current and potential PrEP users in Birmingham, Alabama. AIDS Behav. 2019;23(11):2966–2979.
    1. Ojikutu BO, Bogart LM, Mayer KH, Stopka TJ, Sullivan PS, Ransome Y. Spatial access and willingness to use pre-exposure prophylaxis among black/African American individuals in the United States: cross-sectional survey. JMIR Public Health Surveill. 2019;5:e12405.
    1. Roth AM, Aumaier BL, Felsher MA, et al. An exploration of factors impacting preexposure prophylaxis eligibility and access among syringe exchange users. Sex Transm Dis. 2018;45:217–221.
    1. Hubach RD, Currin JM, Sanders CA, et al. Barriers to access and adoption of pre-exposure prophylaxis for the prevention of HIV among men who have sex with men (MSM) in a relatively rural state. AIDS Educ Prev. 2017;29:315–329.
    1. Doblecki-Lewis S, Butts S, Botero V, Klose K, Cardenas G, Feaster D. A randomized study of passive versus active PrEP patient navigation for a heterogeneous population at risk for HIV in South Florida. J Int Assoc Provid AIDS Care. 2019;18:2325958219848848.
    1. Park CJ, Taylor TN, Gutierrez NR, Zingman BS, Blackstock OJ. Pathways to HIV pre-exposure prophylaxis among women prescribed PrEP at an urban sexual health clinic. J Assoc Nurses AIDS Care. 2019;30:321–329.
    1. Siegler AJ, Bratcher A, Weiss KM, Mouhanna F, Ahlschlager L, Sullivan PS. Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States. Ann Epidemiol. 2018;28:858–864.
    1. Bazzi A, Childs E, Valente P, et al. Challenges implementing pre-exposure prophylaxis (PrEP) for people who inject drugs in non-urban areas of the United States. 10th IAS Conference on HIV Science 2019, Mexico City.
    1. Biello KB, Bazzi AR, Mimiaga MJ, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15:55.
    1. Kolata G. Facing legal action, insurer now will cover people taking Truvada, an H.I.V.-prevention drug; 2019. . Accessed 7 Jan 2020.
    1. Sax P. A urologist, PrEP, and discriminatory disability insurance practices: Dr. Paul Sax interviews Dr. Philip Cheng. Open Forum Infect Dis. 2018;5:ofy149-ofy.
    1. Lee R. Publix grocery chain denies PrEP coverage to its employees; 2018. . Accessed 7 Jan 2020.
    1. Calabrese SK, Magnus M, Mayer KH, et al. Putting PrEP into practice: lessons learned from early-adopting U.S. providers’ firsthand experiences providing HIV pre-exposure prophylaxis and associated care. PLoS One. 2016;11:e0157324.
    1. Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11:1060–1075.
    1. Rowniak S, Ong-Flaherty C, Selix N, Kowell N. Attitudes, beliefs, and barriers to PrEP among trans men. AIDS Educ Prev. 2017;29:302–314.
    1. Poteat T, Wirtz A, Malik M, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among black and Latina transgender women. J Acquir Immune Defic Syndr. 2019;82:131–140.
    1. Blum C. Talking about PrEP and HIV treatment in a time of class action lawsuits; 2019. . Accessed 10 Oct 2019.
    1. Adrover C, Bodnar T, Huang Z, Telenti A, Salathé M. Identifying adverse effects of HIV drug treatment and associated sentiments using Twitter. JMIR Public Health Surveill. 2015;1:e7.
    1. Kakalou C, Lazarus JV, Koutkias V. Mining social media for perceptions and trends on HIV pre-exposure prophylaxis. Stud Health Technol Inform. 2019;264:959–963.
    1. Hill BS, Patel VV, Haughton LJ, Blackstock OJ. Leveraging social media to explore black women’s perspectives on HIV pre-exposure prophylaxis. J Assoc Nurses AIDS Care. 2018;29:107–114.
    1. Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26:684–693.
    1. Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.
    1. Newman R, Katchi T, Karass M, et al. Enhancing HIV pre-exposure prophylaxis practices via an educational intervention. Am J Ther. 2019;26:e462–e468.
    1. Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22:e25252.
    1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–2090.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434.
    1. Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22:3681–3691.
    1. Adams JL, Shelley K, Nicol MR. Review of real-world implementation data on emtricitabine-tenofovir disoproxil fumarate as HIV pre-exposure prophylaxis in the United States. Pharmacotherapy. 2019;39:486–500.
    1. Mayer KH, Chan PA, Patel R, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr. 2018;77:119–127.
    1. Koechlin FM, Fonner VA, Dalglish SL, et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21:1325–1335.
    1. Hannaford A, Lipshie-Williams M, Starrels JL, et al. The use of online posts to identify barriers to and facilitators of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: a comparison to a systematic review of the peer-reviewed literature. AIDS Behav. 2018;22:1080–1095.
    1. Peng P, Su S, Fairley CK, et al. A global estimate of the acceptability of pre-exposure prophylaxis for HIV among men who have sex with men: a systematic review and meta-analysis. AIDS Behav. 2018;22:1063–1074.
    1. Scholl E. Improving outpatient implementation of preexposure prophylaxis in men who have sex with men. J Am Assoc Nurse Pract. 2016;28:446–452.
    1. Vaitses Fontanari AM, Zanella GI, Feijo M, Churchill S, Rodrigues Lobato MI, Costa AB. HIV-related care for transgender people: a systematic review of studies from around the world. Soc Sci Med. 2019;230:280–294.
    1. Pacifico de Carvalho N, Mendicino CCP, Candido RCF, Alecrim DJD, Menezes de Padua CA. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. AIDS Care. 2019;31:1234–1240.
    1. Chapman Lambert C, Marrazzo J, Amico KR, Mugavero MJ, Elopre L. PrEParing women to prevent HIV: an integrated theoretical framework to PrEP black women in the United States. J Assoc Nurses AIDS Care. 2018;29:835–848.
    1. Bradley E, Forsberg K, Betts JE, et al. Factors affecting pre-exposure prophylaxis implementation for women in the United States: a systematic review. J Womens Health (Larchmt) 2019;28:1272–1285.
    1. Raifman J, Nunn A, Oldenburg CE, et al. An evaluation of a clinical pre-exposure prophylaxis education intervention among men who have sex with men. Health Serv Res. 2018;53:2249–2267.
    1. Hygiene NYCDoHaM. Learn about HIV and AIDS; 2019. . Accessed 2 Sep 2019.
    1. The National LGBT Health Education Center. . Accessed 11 Nov 2019.
    1. Dehlin JM, Stillwagon R, Pickett J, Keene L, Schneider JA. #PrEP4Love: an evaluation of a sex-positive HIV prevention campaign. JMIR Public Health Surveill. 2019;5:e12822.
    1. Sophus AI, Mitchell JW. A review of approaches used to increase awareness of pre-exposure prophylaxis (PrEP) in the United States. AIDS Behav. 2019;23:1749–1770.
    1. Patel VV, Ginsburg Z, Golub SA, et al. Empowering with PrEP (E-PrEP), a peer-led social media-based intervention to facilitate HIV preexposure prophylaxis adoption among young black and Latinx gay and bisexual men: protocol for a cluster randomized controlled trial. JMIR Res Protoc. 2018;7:e11375.
    1. Wade Taylor S, Mayer KH, Elsesser SM, Mimiaga MJ, O’Cleirigh C, Safren SA. Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP naive men. AIDS Behav. 2014;18:871–879.
    1. Shaeer KM, Sherman EM, Shafiq S, Hardigan P. Exploratory survey of Florida pharmacists’ experience, knowledge, and perception of HIV pre-exposure prophylaxis. J Am Pharm Assoc. 2014;54:610–617.
    1. Traeger MW, Cornelisse VJ, Asselin J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA. 2019;321:1380–1390.
    1. Mayer KH, Maloney KM, Levine K, et al. Sociodemographic and clinical factors associated with increasing bacterial sexually transmitted infection diagnoses in men who have sex with men accessing care at a Boston community health center (2005–2015) Open Forum Infect Dis. 2017;4:ofx214.
    1. Newcomb ME, Moran K, Feinstein BA, Forscher E, Mustanski B. Pre-exposure prophylaxis (PrEP) use and condomless anal sex: evidence of risk compensation in a cohort of young men who have sex with men. J Acquir Immune Defic Syndr. 2018;77:358–364.
    1. Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1917134.
    1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.
    1. Hare CB, Coll J, Ruane P, et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis [Abstract]. Conference on retroviruses and opportunistic infections, Seattle; 2019.
    1. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–1983.
    1. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;7:CD007189.
    1. Rojas Castro D, Delabre RM, Molina JM. Give PrEP a chance: moving on from the “risk compensation” concept. J Int AIDS Soc. 2019;22(Suppl 6):e25351.
    1. Quaife M, MacGregor L, Ong JJ, et al. Risk compensation and STI incidence in PrEP programmes. Lancet HIV. 2019. 10.1016/S2352-3018(19)30333-9.
    1. Volk JE, Nguyen DP, Hare CB, Marcus JL. HIV infection and drug resistance with unsupervised use of HIV pre-exposure prophylaxis. AIDS Res Hum Retroviruses. 2018;34:329–330.
    1. World Health Organization, WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 1: clinical. Geneva: World Health Organization; 2017 (WHO/HIV/2017.17). Licence: CC BY-NC-SA 3.0 IGO.
    1. Highleyman L. US Preventive Services Task Force press release; 2019. . Accessed 15 Aug 2019.
    1. US Preventive Services Task Force Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321:2203–2213.
    1. Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada whores”. Am J Public Health. 2015;105:1960–1964.
    1. Liu AY, Coleman K, VIttinghoff E, et al. Assessing the PrEP continuum in the San Francisco Bay area: the quickie mobile survey. Conference on retroviruses and opportunistic infections, Seattle; 2019.
    1. Underhill K, Morrow KM, Colleran CM, et al. Access to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US. PLoS One. 2014;9:e112425.
    1. Kelen GD, Rothman RE. Emergency department-based HIV testing: too little, but not too late. Ann Emerg Med. 2009;54:65–71.
    1. Kelley-Ross Pharmacy Group. One-step PrEP. . Accessed 2 Sep 2019.
    1. Tung E, Thomas A, Eichner A, Shalit P. Feasibility of a pharmacist-run HIV PrEP clinic in a community pharmacy setting. Conference on retroviruses and opportunistic infections, Boston; 2017.
    1. Tung EL, Thomas A, Eichner A, Shalit P. Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. Sex Health. 2018;15:556–561.
    1. World Health Organization. Serving the needs of key populations: case examples of innovation and good practice in HIV prevention, diagnosis, treatment and care; 2017. . Accessed 7 Jan 2020.
    1. Iowa TelePrEP. TelePrEP. . Accessed 15 Aug 2019.
    1. Siegler AJ, Mayer KH, Liu AY, et al. Developing and assessing the feasibility of a home-based preexposure prophylaxis monitoring and support program. Clin Infect Dis. 2019;68:501–504.
    1. Vaidya A, Malebranche D, Cantos D, Lora M. Re-framing PrEP: design and implementation of a dynamic, health-focused, pharmacy-based PrEP program in a large county hospital system in the Southeast US. APHA 2019 Annual Meeting and Expo 2019, Philadelphia.
    1. Smith DK, Van Handel M, Huggins R. Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States, 2015. J Acquir Immune Defic Syndr. 2017;76:465–472.
    1. What is ‘Ending the HIV epidemic: a plan for America’? . Accessed 11 Nov 2019.
    1. Khalili J, Landovitz RJ. HIV preexposure prophylaxis—the role of primary care clinicians in ending the HIV epidemic. JAMA Intern Med. 2019;180:126–30.
    1. Rosenberg J. Harris introduces Bill that would require all insurance plans to cover PrEP and related services; 2019. . Accessed 7 Jan 2020.
    1. Pre-exposure prophylaxis assistance program (PrEP-AP). . Accessed 2 Sep 2019.
    1. Pre-exposure prophylaxis drug assistance program (PrEP DAP). . Accessed 2 Sep 2019.
    1. Pre-exposure prophylaxis (PrEP). . Accessed 2 Sep 2019.
    1. Washington State Department of Health. Pre-exposure prophylaxis drug assistance program (PrEP DAP). . Accessed 9 Oct 2019.
    1. Malcolm N, Marx K, Hart J, et al. Decision-making guide for the provision of PrEP services in Title X-funded family planning service sites. Rockville: U.S. Department of Health and Human Services, Office of Population Affairs; 2019.
    1. Eaton LA, Matthews DD, Driffin DD, et al. A multi-US city assessment of awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among black men and transgender women who have sex with men. Prev Sci. 2017;18:505–516.
    1. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30:9–17.
    1. Sales JM, Cwiak C, Haddad LB, et al. Brief report: impact of PrEP training for family planning providers on HIV prevention counseling and patient interest in PrEP in Atlanta, Georgia. J Acquir Immune Defic Syndr. 2019;81:414–418.
    1. Patel AS, Goparaju L, Sales JM, et al. Brief report: PrEP eligibility among at-risk women in the Southern United States: associated factors, awareness, and acceptability. J Acquir Immune Defic Syndr. 2019;80:527–532.
    1. Hirschhorn L, Brown R, Friedman EE, et al. Women’s PrEP knowledge, attitudes, preferences and experience in Chicago. Conference on retroviruses and opportunistic infections, Seattle; 2019.
    1. Reisner SL, Moore CS, Asquith A, et al. High risk and low uptake of pre-exposure prophylaxis to prevent HIV acquisition in a national online sample of transgender men who have sex with men in the United States. J Int AIDS Soc. 2019;22:e25391.
    1. Marcus JL, Hurley LB, Dentoni-Lasofsky D, et al. Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. AIDS Care. 2019;31:536–544.
    1. Ojikutu BO, Bogart LM, Higgins-Biddle M, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the National Survey on HIV in the Black Community (NSHBC) AIDS Behav. 2018;22:3576–3587.
    1. Finlayson T, Cha S, Denson D, et al. Changes in HIV PrEP awareness and use among men who have sex with men, 2014 vs 2017. Conference on retroviruses and opportunistic infections, Seattle; 2019.
    1. Restar AJ, Kuhns L, Reisner SL, Ogunbajo A, Garofalo R, Mimiaga MJ. Acceptability of antiretroviral pre-exposure prophylaxis from a cohort of sexually experienced young transgender women in two U.S. cities. AIDS Behav. 2018;22:3649–3657.
    1. Santa Maria D, Gallardo KR, Narendorf S, et al. Implications for PrEP uptake in young adults experiencing homelessness: a mixed methods study. AIDS Educ Prev. 2019;31:63–81.
    1. Melhado T, Salami T, Olutoye O, Allison W. Perceptions of HIV risk and knowledge of HIV prevention strategies among young minorities recently diagnosed with HIV infection in South Texas, Unites States (U.S.). 10th IAS Conference on HIV Science, Mexico City; 2019.
    1. Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29:1351–1358.
    1. Bunting S, Saqueton R, Batteson T. Leveraging interprofessional student collaboration to educate healthcare providers and increase access to pre-exposure prophylaxis: results of a novel educational approach. 10th IAS Conference on HIV science, Mexico City; 2019.
    1. Blumenthal J, Jain S, Mulvihill E, et al. Perceived versus calculated HIV risk: implications for pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr. 2019;80:e23–e29.
    1. Biello KB, Edeza A, Montgomery MC, Almonte A, Chan PA. Risk perception and interest in HIV pre-exposure prophylaxis among men who have sex with men with rectal gonorrhea and chlamydia infection. Arch Sex Behav. 2019;48:1185–1190.
    1. Mansergh G, Sullivan P, Hirshfield S, Stephenson R. Assessing sexual event-level substance use and risk behavior for HIV infection in a diverse sample of HIV-negative MSM in the era of PrEP, 2018. 10th IAS Conference on HIV science, Mexico City; 2019.
    1. Carley T, Siewert E, Naresh A. Interest in pre-exposure prophylaxis (PrEP) for HIV is limited among women in a general obstetrics and gynecology setting. AIDS Behav. 2019;23(10):2741–2748.
    1. Philbin MM, Parish C, Kinnard EN, et al. Women’s perceived barriers and facilitators towards long-acting injectable pre-exposure prophylaxis (PrEP): results from six cities across the United States. 10th IAS Conference on HIV science, Mexico City; 2019.
    1. Brooks RA, Nieto O, Landrian A, Fehrenbacher A, Cabral A. Experiences of pre-exposure prophylaxis (PrEP)-related stigma among black MSM PrEP users in Los Angeles. J Urban Health. 2019 doi: 10.1007/s11524-019-00371-3.
    1. Thomann M, Grosso A, Zapata R, Chiasson MA. ‘WTF is PrEP?’: attitudes towards pre-exposure prophylaxis among men who have sex with men and transgender women in New York City. Cult Health Sex. 2018;20:772–786.
    1. Biello KB, Hosek S, Drucker MT, et al. Preferences for injectable PrEP among young U.S. cisgender men and transgender women and men who have sex with men. Arch Sex Behav. 2018;47:2101–2107.
    1. Jackman K-M, Kane J, Murray S, et al. Predictors of anticipated healthcare stigma among adult men who have sex with men in the United States and across sub-Saharan African countries. 10th IAS Conference on HIV science, Mexico City; 2019.
    1. Calabrese SK, Dovidio JF, Tekeste M, et al. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr. 2018;79:46–53.
    1. Cyrus E, Villalba K, Jean-Gilles M, et al. Barriers and facilitators of PrEP use: a synthesis of proceedings of the Empowering Women’s Health Summit, Miami, FL, 2018. 10th IAS conference on HIV science, Mexico City; 2019.
    1. Blumenthal J, Morris S, Jain S, et al. HIV risk and characteristics of women seeking PrEP in a US demonstration project. Conference on retroviruses and opportunistic infections, Seattle; 2019.
    1. Holloway IW, Tan D, Gildner JL, et al. Facilitators and barriers to pre-exposure prophylaxis willingness among young men who have sex with men who use geosocial networking applications in California. AIDS Patient Care STDS. 2017;31:517–527.
    1. Flores D, Meanley S, Bauermeister J. Family characteristics in sex communication and social support: implications for emerging adult men who have sex with men’s PrEP engagement. 10th IAS conference on HIV science, Mexico City; 2019.
    1. Meanley S, Magnus M, Connochie D, Bauermeister JA. Indications for PrEP and engagement along the PrEP continuum among emerging adult men who have sex with men in the Mid-Atlantic United States. 10th IAS Conference on HIV science, Mexico City; 2019.
    1. Matson M, Nery-Hurwit M, Jozsa K, Greene G, Macapagal K. Knowledge about pre-exposure prophylaxis (PrEP) among sexual and gender minority (SGM) adolescents assigned male at birth in the United States (US). 10th IAS Conference on HIV Science, Mexico City; 2019.
    1. Reif S, Wilson E, McAllaster C. Perceptions and impact of HIV stigma among high risk populations in the US Deep South. J HIV AIDS. 2018 doi: 10.16966/2380-5536.154.
    1. Crawford N, Chamberlain A, Onwubiko U, Josma D, Morris J. Willingness to screen for pre-exposure prophylaxis in pharmacies among men who have sex with men. 10th IAS conference on HIV science, Mexico City; 2019.
    1. Peterson M, Nowotny K, Dauria E, Arnold T, Brinkley-Rubinstein L. Institutional distrust among gay, bisexual, and other men who have sex with men as a barrier to accessing pre-exposure prophylaxis (PrEP) AIDS Care. 2019;31:364–369.
    1. Maksut JL, Eaton LA, Siembida EJ, Fabius CD, Bradley AM. Health care discrimination, sex behavior disclosure, and awareness of pre-exposure prophylaxis among black men who have sex with men. Stigma Health. 2018;3:330–337.
    1. Quinn K, Dickson-Gomez J, Zarwell M, Pearson B, Lewis M. “A gay man and a doctor are just like, a recipe for destruction”: how racism and homonegativity in healthcare settings influence PrEP uptake among young black MSM. AIDS Behav. 2019;23:1951–1963.
    1. Tekeste M, Hull S, Dovidio JF, et al. Differences in medical mistrust between Black and white women: implications for patient-provider communication about PrEP. AIDS Behav. 2019;23:1737–1748.
    1. Jaiswal J, Griffin M, Singer SN, et al. Structural barriers to pre-exposure prophylaxis use among young sexual minority men: the P18 cohort study. Curr HIV Res. 2018;16:237–249.
    1. Jain JP, Strathdee SA, Patterson TL, et al. Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: a latent class analysis. AIDS Care. 2019 doi: 10.1080/09540121.2019.1626338.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren